Eledon Pharmaceuticals, Inc. ELDN

ELDN Company Overview

Eledon Pharmaceuticals, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing immune-modulating therapies for organ transplantation and immune-mediated diseases. The company’s primary therapeutic platform centers on targeting the CD40 ligand (CD40L) pathway, which plays a key role in immune activation and transplant rejection. Eledon operates within the biotechnology and biopharmaceutical industries, with an emphasis on next-generation immunosuppression approaches intended to improve long-term transplant outcomes while potentially reducing the toxicities associated with conventional therapies.

The company’s lead product candidate is tegoprubart (formerly known as AT-1501), an investigational anti-CD40L monoclonal antibody being evaluated primarily in organ transplantation settings, including kidney and islet cell transplantation. Eledon’s strategic positioning is based on the potential for CD40L blockade to provide targeted immune control without some of the safety limitations historically associated with earlier immunosuppressive regimens. The company evolved through a series of corporate transitions and strategic refocusing efforts, including prior operations under different therapeutic priorities before concentrating primarily on transplantation immunology and biologics development.